Table 2.
Characteristic | Placebo-Controlled Studies | Comparator Studies |
---|---|---|
N studies | 62 | 49 |
N medication treatment groups | 126 | 99 |
N patients in medication treatment groups | 13,676 | 8,734 |
N placebo treatment groups | 62 | 0 |
N patients in placebo treatment groups | 6,750 | 0 |
Mean age | 41.1 ± 2.5 | 42.1 ± 3.5 |
Mean drop-out rate | 31.8 ± 14.1 | 24.0 ± 10.2 |
Mean N ITTa | 108.9 ± 56.7 | 88.2 ± 52.3 |
Mean pre-treatment HRSDb | 24.6 ± 3.6 | 26.1 ± 4.8 |
N treatment conditions | N patients | N treatment conditions | N patients | |
---|---|---|---|---|
| ||||
Study duration | ||||
6 wks | 77 | 5,999 | 55 | 3,592 |
8 wks | 92 | 12,169 | 36 | 4,218 |
12 wks | 4 | 503 | 8 | 924 |
| ||||
Study visits | ||||
Weekly | 66 | 4,750 | 20 | 1,148 |
Skip 1 visit | 29 | 3,146 | 4 | 589 |
Skip 2 visits | 55 | 8,088 | 32 | 2,611 |
Skip ≥3 visits | 45 | 4,369 | 35 | 3,748 |
| ||||
Meds used | ||||
SSRIc | 53 | 5,812 | 54 | 4,986 |
SNRId | 40 | 4,700 | 15 | 1,762 |
TCAe | 16 | 1,096 | 12 | 733 |
Atypical ADf | 15 | 1,835 | 17 | 1,230 |
MAOIg | 2 | 233 | 1 | 23 |
ITT = Intent to treat
HRSD = Hamilton Rating Scale for Depression
SSRI = Selective Serotonin Reuptake Inhibitor
SNRI = Serotonin Norepinephrine Reuptake Inhibitor
TCA = Tricyclic antidepressant
Atypical AD = Atypical antidepressant (e.g., bupropion, nefazodone, mirtazipine, trazodone)
MAOI = Monoamine Oxidase Inhibitor